oncology

Cellectar Biosciences Inc (NASDAQ: CLRB) shares are pushing northward on over five times their average volume after the company reported positive results from an ongoing midstage trial. Cellectar shares were advancing more than 20 percent to $9 at the time of publication Tuesday. What Happened...

Loxo Oncology Inc (NASDAQ: LOXO) is up 280 percent year-over-year — and, by one estimate, still has room to run. The Rating Piper Jaffray analyst Tyler Van Buren initiated coverage with an Overweight rating and a $200 price target. The Thesis Piper Jaffray sees promise in Loxo’s TRK...

Oncological drug developers have fierce competition for patients, both in trials and in market. But Moleculin Biotech Inc (NASDAQ: MBRX) rests secure, snugly insulated from the battle. “There’s a reason not a lot of people are playing in the sandbox we’re playing in,”...

Foundation Medicine Inc (NASDAQ: FMI), a manufacturer of genomic analysis diagnostics for solid and circulating cancer, is  uniquely positioned in comprehensive cancer profiling, a Cowen analyst said.  The Analyst Cowen analyst Doug Schenkel initiated coverage of Foundation Medicine...

Miragen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotech company, has product candidates for hematologic cancers and fibrotic diseases in its pipeline. The Analyst Oppenheimer analyst Leah Rush Cann initiated coverage of Miragen with an Outperform and a 12-18-month price...

The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was all about competition in the CART-T space. Immunotherapy — the fifth pillar of...

Genocea Biosciences Inc (NASDAQ: GNCA) announced a 40-percent workforce reduction Monday as it officially shifts focus to immuno-oncology and neoantigen cancer vaccines and explores strategic alternatives for its former lead candidate. The Street reacted with a sharp pullback and a Tuesday ratings...

The ESMO 2016 Oncology Conference took place over the weekend in Copenhagen, Denmark. News out of the conference is making a big splash in the market on Monday. Here’s a look at what you may have missed. Bristol-Myers Squibb Co (NYSE: BMY) shares are down 10.17 percent after the company...

Barclays found that TESARO Inc (NASDAQ: TSRO)'s final stage results on NOVA and its indication to pursue a wider label for the drug means a setback for Myriad Genetics, Inc. (NASDAQ: MYGN) and its myChoice HRD. As a result, Myriad stock traded down by more than 7 percent on Monday. The firm reduced...

BMO Capital’s M. Ian Somaiya expects higher probability of success for Incyte Corporation (NASDAQ: INCY)'s epacadostat+Keytruda trials in melanoma, given the PFS strength in the updated Phase I data presented at the meeting of the European Society for Medical Oncology. Somaiya maintains an...

BTIG has started coverage of Kite Pharma Inc (NASDAQ: KITE) with a Neutral rating, as it is skeptical over current investor expectations for the CD19 CAR T market, given the limited datasets and potential competition from CD19 bi-specific antibodies. Kite is pursuing Chimeric Antigen Receptor T-...

Rodman & Renshaw initiated coverage on OncoSec Medical Inc (NASDAQ: ONCS) with a Buy rating and $6.00 price target, describing the company as representing a unique opportunity in the oncology sector, positioned in the highly visible and widely-followed immunotherapy domain. Related Link:...

Eli Lilly and Co (NYSE: LLY) detailed in a presentation to the investment community its outlook for new product launches through 2023. Eli Lilly said that it has the potential to launch a total of 20 new products in the 10-year period beginning in 2014 and extending through 2023. In addition, the...

Natera Inc (NASDAQ: NTRA), a provider of genetic testing services, looks to raise $100 million in its IPO Thursday. Natera priced 10 million shares at $18. The company will list on the NASDAQ under the ticker NTRA. Diagnostic companies going public have been met with mixed feelings. Based in...